PHOENIX, Dec. 04, 2018 (GLOBE NEWSWIRE) — Pharmaceutical-grade cannabidiol (CBD) oral solution made by INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, was generally well-tolerated—even at high doses—as an investigational treatment for refractory pediatric epilepsy, according to new clinical …
Tag Archives: insys
December, 2018
August, 2018
-
30 August
FDA Grants Insys’ Epinephrine Nasal Spray Fast Track Designation as Investigational Treatment for Anaphylaxis
PHOENIX, Aug. 30, 2018 (GLOBE NEWSWIRE) — INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s epinephrine nasal spray as an investigational treatment for …
December, 2017
-
27 December
INSYS’ Cannabidiol Solution Receives FDA Fast Track Designation as Treatment for Prader-Willi Syndrome
PHOENIX, Dec. 26, 2017 (GLOBE NEWSWIRE) — INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s cannabidiol (CBD) oral solution for the treatment of Prader-Willi syndrome, a rare and complex genetic disorder characterized by insatiable appetite in children that …
July, 2016
-
5 July
FDA Approves Insys’ Cannabis-Based Drug for Cancer, AIDS-Related Weight Loss
PHOENIX, July 05, 2016 (GLOBE NEWSWIRE) — Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that the U.S. Food and Drug Administration (FDA) has approved Insys’ dronabinol oral solution, SyndrosTM, an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol (“THC”). Syndros is …
January, 2015
-
27 January
Insys’ Ovarian Cancer Treatment Receives Orphan Drug Designation from the FDA
The US Food and Drug Administration (FDA) granted Orphan Drug designation for Insys Therapeutics’ ovarian cancer candidate. The agency granted the designation to Insys’ Liposomal Encapsulated Paclitaxel (LEP) candidate for the treatment of ovarian cancer. The FDA’s Office of Orphan Products Development grants novel drugs or biologics that treat rare …